Details for Patent: 11,007,175

Which drugs does patent 11,007,175 protect, and when does it expire?

Patent 11,007,175 protects VELSIPITY and is included in one NDA.

This patent has twenty-four patent family members in twelve countries.

Summary for Patent: 11,007,175

Title:	Methods of treating conditions related to the S1Preceptor
Abstract:	Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoro-methyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.
Inventor(s):	Glicklich Alan, Kam Maria Matilde Sanchez, Shanahan William R.
Assignee:	Arena Pharmaceuticals, Inc.
Application Number:	US15541496
Patent Claim Types: see list of patent claims

Understanding the Scope and Claims of United States Patent 11,007,175

Introduction

United States Patent 11,007,175, titled "Methods of treating conditions related to the S1P1 receptor," is a patent that delves into innovative methods for treating various conditions associated with the sphingosine 1-phosphate subtype 1 (S1P1) receptor. This analysis will explore the patent's scope, claims, and the broader patent landscape in which it resides.

Patent Overview

The patent, assigned to a specific entity (though not specified in the provided sources), focuses on therapeutic methods involving the S1P1 receptor. Here is a brief overview:

• Publication Number: US11007175B2
• Filing Date: Derived from the application number US201615541496A, indicating a filing date in 2016.
• Grant Date: The patent was granted, but the exact date is not specified in the sources provided[4].

Claims Analysis

The claims of a patent are crucial as they define the scope of the invention and what is protected by the patent.

Independent Claims

Independent claims are standalone claims that do not rely on other claims for their validity. For Patent 11,007,175, the independent claims typically would include:

• Claim 1: This usually sets the broadest scope of the invention, such as methods for treating S1P1 receptor-associated disorders.
• Subsequent Claims: These may narrow down the scope by specifying particular compounds, dosages, or treatment protocols.

Dependent Claims

Dependent claims build upon the independent claims, adding additional limitations to further define the invention. For example:

• Claim 2: Might specify a particular compound or its acceptable salt, solvate, or hydrate, used in the treatment method.
• Claim 3: Could detail a specific dosage regimen or administration route.

Patent Scope

The scope of a patent is determined by its claims and the description provided in the specification.

Independent Claim Length and Count

Research suggests that narrower claims, as measured by independent claim length and count, are associated with a higher probability of grant and a shorter examination process. Broader claims, on the other hand, may face more scrutiny and potentially longer examination times[3].

Claim Language and Scope

The language used in the claims is critical. For Patent 11,007,175, the claims would need to be precise and clear to avoid ambiguity and ensure enforceability. The scope would be defined by the specific methods, compounds, and treatment protocols outlined.

Patent Landscape

The patent landscape for S1P1 receptor-related treatments is complex and evolving.

Competing Patents

Other patents in the same field may cover similar or overlapping subject matter. For instance, patents related to other sphingosine 1-phosphate receptor subtypes or different therapeutic approaches could be relevant.

Litigation and Validity

Patents are presumed valid under U.S. law (35 USC 282), but they can still face challenges. Litigation, such as that seen in cases like Allergan USA, Inc. v. MSN Laboratories Private Ltd., can arise over issues like obviousness-type double patenting or lack of written description[2].

Examination Process

The examination process for Patent 11,007,175 would have involved several key steps:

Filing and Prosecution

The patent application would have been filed with the USPTO, followed by a period of prosecution where the examiner reviews the application for novelty, non-obviousness, and other statutory requirements.

Continuations and Amendments

The applicant might have filed continuations or amendments to address examiner objections or to clarify the claims. This process can significantly impact the final scope and validity of the patent[1].

Economic and Innovation Impact

Patents like 11,007,175 play a crucial role in incentivizing innovation by providing exclusive rights to the patent holder.

Licensing and Litigation Costs

The breadth and clarity of patent claims can affect licensing and litigation costs. Narrower, clearer claims tend to reduce these costs and promote innovation[3].

Forward Citations and Maintenance Payments

The number of forward citations (citations by later patents) and maintenance payments can indicate the patent's impact and value. Patents with higher forward citations and consistent maintenance payments are generally considered more valuable and influential[3].

Key Takeaways

• Claims and Scope: The claims of Patent 11,007,175 define its scope and protection, with independent claims setting the broadest scope and dependent claims adding specificity.
• Patent Landscape: The patent operates within a complex landscape of competing patents and potential litigation.
• Examination Process: The patent's examination involved filing, prosecution, and possibly continuations or amendments.
• Economic Impact: The patent's clarity and breadth influence its economic impact, including licensing and litigation costs.

FAQs

1. What is the primary focus of United States Patent 11,007,175?

   • The primary focus is on methods for treating conditions related to the S1P1 receptor.

2. How are the claims of a patent structured?

   • Claims are structured into independent and dependent claims, with independent claims defining the broadest scope and dependent claims adding additional limitations.

3. What factors influence the scope of a patent?

   • The scope is influenced by the language and breadth of the claims, as well as the description provided in the specification.

4. How does the examination process impact the final patent?

   • The examination process, including any continuations or amendments, can significantly impact the final scope and validity of the patent.

5. What is the economic impact of a patent like 11,007,175?

   • The patent can incentivize innovation by providing exclusive rights, but its economic impact also depends on factors like licensing and litigation costs, which are influenced by the clarity and breadth of the claims.

Cited Sources:

1. Carley, M., & Hegde, D. (n.d.). What Is the Probability of Receiving a US Patent? The Yale Journal of Law & Technology.
2. United States Court of Appeals for the Federal Circuit. (2024). ALLERGAN USA, INC. v. MSN LABORATORIES PRIVATE LTD.
3. SSRN. (2016). Patent Claims and Patent Scope.
4. Google Patents. (n.d.). US11007175B2 - Methods of treating conditions related to the S1P1 receptor.

Drugs Protected by US Patent 11,007,175

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956-001	Oct 12, 2023		RX	Yes	Yes						A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING ESTRASIMOD ARGININE IN AN AMOUNT EQUIVALENT TO ABOUT 2.0 MG OF ESTRASIMOD

International Family Members for US Patent 11,007,175

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016205361
Australia	2021200129
Australia	2022283660
Canada	3002540